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Combination treatment with n-3 
polyunsaturated fatty acids and 
ursodeoxycholic acid dissolves 
cholesterol gallstones in mice
Sung ill Jang  1, Sungsoon fang2, Kwang pyo Kim  3, Younhee Ko4, Hyoseon Kim3, 
Jieun oh3, Ga Young Hong5, Su Yeon Lee1, Joon Mee Kim6, ilkoo noh7 & Dong Ki Lee  1
the increasing prevalence of cholesterol gallstone disease places an economic burden on the healthcare 
system. To identify novel therapeutics, we assessed the effects of n-3 polyunsaturated fatty acids 
(pUfA) in combination with UDcA in a mouse model of cholesterol gallstones. Gallstone dissolution, 
gallbladder wall thickness, mucin gene expression in the gallbladder, and levels of phospholipids, 
cholesterol, and bile acids in bile and serum were analysed. RnA was extracted from the liver for 
mRNA sequencing and gene expression profiling. Combination treatment resulted in greater gallstone 
dissolution compared with the control group, and pUfA and combination treatments reduced the 
thickness of the gallbladder wall. Expression levels of mucin genes were significantly lower in the 
UDcA, pUfA, and combination groups. transcriptome analyses revealed that combination treatment 
modulated hepatic lipid metabolism. the pUfA and combination groups showed elevated bile 
phospholipid and bile acid levels and a lower cholesterol saturation index. combination treatment with 
pUfA and UDcA dissolves cholesterol gallstones in mice by decreasing mucin production, increasing 
levels of phospholipids and bile acids in bile, and decreasing cholesterol saturation. further studies 
of the therapeutic effects of combination PUFA and UDCA treatment in patients with cholesterol 
gallstones are warranted.
Gallstone disease is an important health problem with gastrointestinal sequelae that frequently leads to admission 
to the hospital1,2 and has a mortality rate of 0.6%1. In the United States, patients with gallstone disease have an 
increased overall mortality rate, particularly due to cardiovascular disease and cancer3. As the incidence of gall-
stone disease increases, so does the incidence of complications such as gallstone-related pancreatitis4.
Cholesterol gallstone disease is associated with an increased concentration of cholesterol relative to that of 
bile salts and phospholipids. When the amounts of biliary lipids, inorganic salts, and/or organic salts in bile acids 
exceed maximum solubility, the acids crystallize through nucleation and eventually form gallstones5. Westernized 
diets, which are high in calories, cholesterol, saturated fatty acids, carbohydrates, and protein and low in dietary 
fiber, promote gallstone formation6,7. For instance, Canadian Eskimos who consume a Western-style diet have an 
increased prevalence of complications due to cholesterol gallstone disease8. Furthermore, the number of patients 
with cholesterol or mixed gallstones has rapidly increased in Asia as the Asian diet has become increasingly 
westernized9,10.
Gallstones are present in 10–20% of the general population, although 80% are asymptomatic11. However, 
serious symptoms and complications that require treatment develop in 1–2% of patients with asymptomatic 
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gallstones annually12. Surgical treatments such as cholecystectomy are standard for symptomatic gallstone dis-
ease, but there are few medical treatment options. Although laparoscopic cholecystectomy is safer than open 
cholecystectomy, it has serious risks13,14. The prevalence of laparoscopic cholecystectomy among gallstone 
patients is 1.6–12%, and its complication rate can reach 1.2%, with bile duct damage being the major cause of 
complications13. Because patients with gallstones who undergo surgical treatment can experience chronic biliary 
pain and gallstone-related complications15, effective medical treatments are required. Since the introduction of 
chenodeoxycholid acid and ursodeoxycholic acid (UDCA) for the treatment of gallstones in the 1970s and 1980s, 
respectively, treatment with oral solvents has replaced high-risk open cholecystectomy16,17.
Epidemiological studies have investigated the potential therapeutic effects of omega-3 polyunsaturated fatty 
acids (PUFAs) against cholesterol gallstones. For instance, Eskimos, who have a diet rich in fish oil (which con-
tains a high level of omega-3 PUFAs and has two major components, eicosapentaenoic acid [EPA, C20:5n-3] and 
docosahexaenoic acid [DHA, C22,6n-3])18, have a lower prevalence of cholesterol gallstones than that of Western 
populations19. In this study, we evaluated the therapeutic effects of PUFA, UDCA, and the combination of PUFA 
and UDCA in a mouse model of cholesterol gallstones.
Results
Gallstone formation. There were no significant differences among groups in body or liver weight before or 
after treatment (Fig. 1A,B), and no systemic side effects were observed. Gallstone weight was significantly lower 
in the combination group than in the control group after treatment (Fig. 1C). In addition, gallstones were signifi-
cantly smaller in the UDCA and combination groups than in the control group (Fig. 1D). A reduction in gallstone 
number and size was observed macroscopically in all treatment groups (Fig. 2A–E).
Gallbladder histology and mucin gene expression. The thickness of the gallbladder wall was signif-
icantly reduced in the PUFA and combination groups compared with the control group (Fig. 3A–F) and was 
associated with a thinning of the mucosal epithelium and a reduction in the height of the gallbladder wall. The 
UDCA, PUFA, and combination groups showed significantly reduced expression of Muc2, Muc5ac, Muc5b, and 
Muc6 in gallbladder tissue compared with the control group (Fig. 3G–I).
total phospholipids, cholesterol, and bile acid. Compared with the control group, the PUFA group 
showed a significant increase in total cholesterol level in bile (Fig. 4A), and the PUFA and combination groups 
showed significant increases in levels of bile acids and phospholipids in bile (Fig. 4B,C). Consistently, the cho-
lesterol saturation index (CSI) was significantly lower in the PUFA and combination groups than in the control 
group (Fig. 4D). There were no differences in total cholesterol level in serum among groups (Fig. 4E), whereas the 
combination group showed a significantly higher serum level of phospholipids than the other groups (Fig. 4F).
classes of phospholipids, cholesterol, and bile acid. We identified 12 cholesteryl esters, 1 cholesterol, 
23 ceramides, 9 sphingomyelins, 3 ceramide 1-phosphates, 50 phosphatidylcholines, 17 lysophosphatidylcholines, 
4 lysophosphatidicacids, 1 phosphatidylserine (PS), 33 bile acids, and 157 lipids in bile using LC/QqQ-MS/MS. To 
compare levels of lipids among groups, we created heatmaps for LC-MS data. Levels of most phospholipid classes 
were higher in the PUFA group than in the control group (Fig. 5A). In addition, the UDCA and combination 
groups showed higher levels of lysophosphatidicacid and ceramide 1-phosphate species than the control group. 
The level of cholesterol was higher in the PUFA and UDCA groups than in the control group (Fig. 5B) but was 
similar between the combination and control groups.
Analysis of bile acid showed higher levels of DHA and EPA in the PUFA group and a higher level of UDCA 
in the UDCA group than in the control group (Fig. 5C), indicating that exogenous dosing of PUFA or UDCA 
resulted in increased levels of these substances. Compared with the control group, the PUFA group showed higher 
levels of hyodeoxycholic acid (HDCA), murocholic acid (MuroCA), UDCA, glycoursodeoxycholic acid, glycohy-
odeoxycholic acid, taurocholate, tauro-ω-mouse cholic acid, cholic acid, hyocholic acid, tauro-β-muricholic acid, 
α-muricholic acid, β-MuroCA, taurochenodeoxycholic acid, taurodeoxycholic acid, taurohyodeoxycholic acid, 
EPA, and DHA. The UDCA group showed higher levels of HDCA, MuroCA, UDCA, glycoursodeoxycholic acid, 
glycohyodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, taurohyodeoxycholic acid, EPA, 
and DHA compared with the control group. The combination and PUFA groups exhibited similar increases in 
levels of bile acid subclasses compared with the control group.
Next, we evaluated levels of lipids in the PUFA, UDCA, and combination groups. The level of PS(36:0) was 
1.5-fold higher in the PUFA and UDCA groups than in the control group (Supplementary Table 1) but was lower 
in the combination group than in the control group. In addition, levels of UDCA, HDCA, and MuroCA were 
1.5-fold higher in the PUFA, UDCA, and combination groups than in the control group.
expression levels of genes related to cholesterol and bile acid production, transport, and 
metabolism. To gain insight into the molecular mechanisms by which combination treatment affects gall-
stone formation, we analysed the expression of genes involved in cholesterol production. Cholesterol is secreted 
by the canalicular transporters ABCG5 and ABCG8. The PUFA and combination groups had lower expression of 
Abcg5 and Abcg8 than in the control group (Fig. 6A). Consistently, the expression of Abcb4, essential for efficient 
secretion of cholesterol from liver into bile, was also decreased in the combination group (Supplementary Fig. S2). 
In addition, the UDCA and combination groups had lower expression of the gene encoding HMG-CoA reductase 
(Hmgcr), the rate-limiting enzyme in cholesterol production (Fig. 6B). Although the expression level of the gene 
for scavenger receptor class B type I (Sr-b1) varied among groups, that of the gene encoding low-density lipopro-
tein receptor (Ldlr) was reduced in the UDCA and combination groups. Together, these results suggest that com-
bination treatment modulates gallstone formation by reducing both canalicular efflux and cholesterol production.
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Next, we analysed the expression levels of genes related to cholesterol metabolism that are also involved in bile 
acid synthesis and transport in the liver. Expression of the gene encoding cholesterol 7a-hydroxylase (Cyp7a1), 
the rate-limiting enzyme in bile acid synthesis, was reduced in the UDCA and combination groups compared 
with the control group (Fig. 6C). Expression of genes for 25-hydroxylcholesterol 7a-hydroxylase (Cyp7b1) and 
Figure 1. Body weight, liver weight, and gallbladder stone weight and size before and after treatments. Body 
weight, liver weight, and gallbladder stone weight and size were checked during the pre-treatment (after the 
feeding with lithogenic diet for 8 weeks) and post-treatment stages (after administration of the therapeutic agent 
with a regular diet for 12 weeks) in the four groups (control, ursodeoxycholic acid [UDCA], polyunsaturated 
fatty acids [PUFA], and combination group). The variables were evaluated in 15 mice in each group during the 
pre-treatment stage, and in 25 mice in each group during the post-treatment stage. No significant differences 
were observed among the groups in (A) body weight or (B) liver weight, and no systemic side effects were 
noted. (C) Gallstone weight decreased significantly in the combination group. (D) Gallstone size, as measured 
using a 6-point grading system, decreased significantly in the UDCA and combination groups. *P < 0.05 vs. 
control group.
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sterol 12a-hydroxylase (Cyp8b1) were unaffected by the treatments, but all three treatment groups showed 
reduced expression of the gene for sterol 27-hydroxylase (Cyp27a1).
Bile acid homeostasis is regulated by systemic bile acid signalling through bile acid transporters. The combi-
nation group exhibited significant decreases in the expression of genes encoding bile-salt exporting pump (Bsep), 
multidrug-resistance protein 2 (Mrp2), Mrp3, Mrp4, and organic anion-transporting polypeptide 1 (Oatp1) 
(Fig. 6C), suggesting suppression of the uptake and sinusoidal export of bile acids in the liver. Consistent with 
gene expression of Bsep, we have also noticed that a well-known nuclear bile acid receptor FXR target gene small 
heterodimer partner (Nr0b2) has been markedly reduced in the combination group, suggesting that combination 
treatment may reduce FXR-mediated transcriptional signalling pathway in the liver (Supplementary Fig. S3).
expression levels of lipogenesis and steatosis-related genes and triglyceride levels. Given our 
observation of reduced cholesterol production after combination treatment, we examined the expression of genes 
related to lipogenesis in the liver. All three treatment groups showed reduced expression of genes for stearoyl-CoA 
desaturase 1 (Scd1), fatty acid synthase (Fas), acetyl-CoA carboxylase (Acc), sterol regulatory element-binding 
protein 1a (Srebp1a), and Srebp1c (Fig. 6D). Next, we examined the expression of genes encoding fatty acid 
transport proteins. In the combination group, the expression of genes for long-chain fatty acid transport protein 
1 (Fatp1), Fatp3, Fatp4, and Fatp5 were decreased (Fig. 6E). These results suggest that combination treatment 
reduced both de novo lipogenesis and fatty acid uptake in the liver.
To verify these gene expression profiles, we examined triglyceride levels in the liver. Consistent with gene 
expression profiles, the PUFA and combination groups exhibited lower hepatic triglyceride levels than the control 
group (Fig. 6F). Furthermore, based on histological analyses of liver tissue, the combination group had markedly 
reduced hepatic steatosis compared with all other groups (Fig. 6G). Therefore, combination treatment reduces de 
novo lipogenesis and fatty acid uptake into hepatocytes, thereby decreasing the level of hepatic triglycerides. In 
Figure 2. Gross findings of the liver, gallbladder, and gallstones. The photographs demonstrate the gross 
findings of the liver, gallbladder, and gallstones. (A) In the pre-treatment stage (after feeding with lithogenic 
diet for 8 weeks), gallstone formation was confirmed and the number and size of the gallstones were measured 
in 15 mice in each of the four groups (B–E). Gallstone number and size were compared between the control 
group (B) and three treatment groups ((C) UDCA group; (D) PUFA group; (E) combination group) during the 
post-treatment stage (after administering the therapeutic agent with the regular diet for 12 weeks). The number 
and size of the gallstones grossly reduced in all three treatment groups (UDCA, PUFA, and combination group) 
compared to the pre-treatment group.
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addition to lipid metabolism, we also have noticed that proinflammatory cytokines were largely downregulated 
in the combination group, implying that combination treatment would have beneficial impacts to reduce hepatic 
inflammation (Supplementary Fig. S4).
Transcriptome analysis of hepatic gene expression profiles. To understand how the treatments 
affected hepatic gene expression profiles, we performed transcriptomic analyses of liver tissue by RNA-seq. 
The expression of 389, 523, and 396 genes was changed by PUFA, UDCA, and combination treatments, respec-
tively (Fig. 7A). In addition, 129 genes were common targets in all treatment groups (Fig. 7B) and showed 
similar expression patterns across groups (Fig. 7B). GO enrichment analyses showed that several metabolic pro-
cesses, including lipid metabolism and cholesterol homeostasis, were modulated by the treatments (Fig. 7C). 
Consistently, all treatments induced changes in metabolic pathways such as PPARγ signalling, insulin signalling, 
gluconeogenesis, and lipolysis regulation (Supplementary Figs 2–4). To evaluate the high-level molecular associ-
ations among these 129 genes, we used EnrichNet (i.e., network-based gene set enrichment analyses) to charac-
terize protein-protein interaction networks (Fig. 7D). Adiponectin (Adipo), lipoprotein lipase (Lpl), Fas, and fatty 
acid binding protein 4 (Fabp4) were the primary hub genes (Fig. 7E), suggesting that hepatic lipid metabolism is 
the major target of the treatments.
Discussion
We found that the combination of UDCA and PUFA resolved cholesterol gallstones without inducing systemic 
side effects, suggesting that this combination may be effective for patients with cholesterol gallstones. PUFA 
increased levels of phospholipids in bile, thereby lowering the CSI, and downregulated the expression of mucin 
genes in gallbladder tissue. This is the first study to evaluate the mechanism underlying the efficacy of treatments 
for gallstones using lipideomics and analysis of hepatic gene expression.
Since Wechsler and colleagues20 reported in 1989 that administration of omega-3 fatty acids for 6 weeks 
reduces biliary cholesterol levels and the CSI in adult men, several studies of the relationships among PUFA, bile, 
and gallstones have been performed. For example, adding fish oil to food reduces biliary phospholipid concen-
trations and the formation of cholesterol monohydrate crystals in prairie dogs21. Fish oil intake may exert these 
effects by enhancing the conversion of arachidonate, a biliary phospholipid, into EPA and DHA, thereby reducing 
biliary cholesterol saturation and suppressing cholesterol crystallization21,22.
Berr et al.23 reported that omega-3 fatty acids reduce biliary cholesterol saturation in humans, and Mizuguchi 
et al.24 showed that administration of EPA inhibits the formation of cholesterol gallstones. Thus, EPA and DHA 
may inhibit HMG-CoA reductase activity in the liver and increase bile secretion, thereby reducing cholesterol 
Figure 3. Histological mucosal changes, thickness of the gallbladder wall, and expression levels of MUC genes 
in the gallbladder. The photographs demonstrate the microscopic features of the gallbladder. (A) Lithogenic diet 
(LD) induced mucosal hypertrophy of the gallbladder in the pre-treatment stage (after feeding the lithogenic 
diet for 8 weeks). (B–E) Gallbladder wall thickening was compared between the control group and three 
treatment groups ((B) control group; (C) UDCA group; (D) PUFA group; and (E) combination group) in the 
post-treatment stage (after administration of the therapeutic agent with the regular diet for 12 weeks). The 
treatments reduced the thickness of the hypertrophied gallbladder wall. (F) The thickness of the gallbladder 
wall decreased significantly in the PUFA and combination groups. (G) Muc2, (H) Muc5ac, (I) Muc5b, and (J) 
Muc6 expression levels in the gallbladder decreased significantly in the UDCA, PUFA, and combination groups. 
*P < 0.05 vs. control group.
6Scientific RepoRtS |         (2019) 9:12740  | https://doi.org/10.1038/s41598-019-49095-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
levels in serum and the liver25. Omega-3 fatty acid might not only increase biliary cholesterol secretion but also 
decrease the lithogenic index, as a simultaneous increase in secretion of both bile acids and phospholipids pre-
vents cholesterol oversaturation25. Given these results, biliary phospholipids, in which cholesterol is soluble, could 
be used to treat gallstones if their molecular structure can be manipulated to increase the concentrations of phos-
pholipids in bile, which would reduce the quantity of cholesterol crystals. In a previous study26, we reported that 
PUFA inhibits the formation of gallstones by suppressing mucin production, although we were unable to identify 
the underlying mechanism. Therefore, in the present study, we investigated the effects of a mixture containing 
UDCA and PUFA on gallstones as well as the underlying mechanism(s).
UDCA is currently used as a therapeutic agent for cholesterol gallstones. In the present study, gallstone forma-
tion tended to decrease in the UDCA group compared to the control, albeit not significantly. This lack of a thera-
peutic effect of UDCA alone may be attributable to the short (i.e., 12-week) administration period, as a previous 
study reported only a 20–30% response rate in humans who took UDCA for 2 years16. Similarly, the therapeutic 
effect in the PUFA group also failed to reach statistical significance. However, the two agents used in combination 
had an additive or synergistic effect on gallstone dissolution, as indicated by the significant decrease in gallstone 
weight and size in the combination group.
Figure 4. The CSI and levels of total cholesterol, phospholipids, and bile acids. (A) Total cholesterol level in the 
bile increased significantly in the PUFA group. (B,C) Both the PUFA and combination groups had significantly 
increased bile acid (B) and total phospholipid levels in bile (C). (D) As a result, the CSI decreased significantly 
in the PUFA and combination groups. (E) Total serum levels of cholesterol were similar among the groups.  
(F) Serum levels of phospholipids increased significantly in the combination group. *P < 0.05 vs. control group.
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To investigate the mechanism by which combination UDCA/PUFA treatment dissolves gallstones, we meas-
ured total levels of cholesterol, phospholipids, and bile acids in bile and serum as well as the CSI, which is based 
on levels of cholesterol, bile acids, and lecithin in bile. The precipitation of cholesterol crystals from supersatu-
rated bile is a prerequisite for gallstone formation6, whereas cholesterol is dissolved by mixed micelles of bile salts 
Figure 5. Heat maps of bile phospholipid, cholesterol, and bile acid classes. Heat map analysis of (A) 
phospholipid classes (e.g., phosphatidylcholine, lysophosphatidylcholine, lipoprotein (a), PS, sphingomyelin, 
dihydroceramide 1-phosphate, ceramide 1-phosphate), (B) cholesteryl ester and cholesterol, and (C) various 
bile acids. Lipid subclass profiles across the four types. Each colored four types on the map depends on a 
concentration value. Data in the heat map of measured by Euclidean distance using Ward clustering algorithm.
8Scientific RepoRtS |         (2019) 9:12740  | https://doi.org/10.1038/s41598-019-49095-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
and phospholipids. Therefore, as the lithogenic index or CSI decreases, the probability of cholesterol gallstone 
formation also decreases27. As lecithin accounts for more than 95% of total phospholipids, we measured the levels 
of phospholipids instead of lecithin. Combination treatment did not affect the total level of bile cholesterol but 
significantly increased the amount of bile acids and phospholipids in bile and thus reduced the CSI. Therefore, 
combination treatment may dissolve gallstones by increasing levels of bile acids and phospholipids in bile, thereby 
altering the CSI. These changes appear to occur only in bile, as cholesterol and phospholipid levels in serum were 
largely unchanged.
Figure 6. Cholesterol and bile acid production and transport, and expression levels of related genes. Hepatic 
expression levels of genes related to (A) canalicular efflux, (B) cholesterol synthesis, (C) bile acid synthesis and 
bile acid transporters, (D) lipogenesis, and (E) fatty acid transporters. Expression levels were normalized to that 
of β-actin. (F) Hepatic triglyceride levels. (G) Microscopic features of the liver. *P < 0.05 and **P < 0.01 vs. 
control group. Data are mean ± standard error of the mean (SEM).
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Biliary mucin protects gallbladder epithelial cells and plays important roles in gallstone formation28,29. Combination 
treatment suppressed the expression of mucin biosynthesis genes, which affected the secretion of mucin in the gallblad-
der. Although mucin overproduction is a prerequisite for gallstone formation, the mechanism underlying enhanced 
mucin secretion during gallstone formation is unclear30. We suggest that combination PUFA and UDCA treatment 
Figure 7. Transcriptome analyses and protein–protein interaction networks. (A) DEGs in the treatment 
groups; 129 DEGs were common across all treatments. (B) Heatmap of log2-fold changes in DEGs. (C) GO 
enrichment analyses of the 129 common target genes; bars represent enrichment scores (−logP-value). (D) 
Physical and functional interactions among the 129 common target genes. (E) Number of degrees for the main 
hub genes in (A).
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increased levels of phospholipids and bile acid in bile, thus lowering the CSI and decreasing gallstone formation. 
Furthermore, combination treatment may have also reduced chemical irritation of the gallbladder mucosa, thereby 
decreasing the expression of mucin biosynthesis genes and mucin production and promoting nucleation in bile.
MS has potential applications in various fields, including pharmaceutical, food, and medical industries. The 
advantage of MS is that it can be used to perform both quantitative and qualitative analyses. It can be used to 
quantitatively analyse a greater variety of lipids than conventional methods, and ultra-performance LC enables 
separation of lipid species. In addition, multiple-reaction monitoring based on QqQ/MS allows highly sensitive 
analyses of target compounds. Using MS, we quantified levels of cholesterol, phospholipids, and bile acids after 
treatment with PUFA and UDCA. Phospholipid levels were highest in the PUFA group, and cholesterol lev-
els were highest in the PUFA and UDCA groups, presumably due to the dissolution of gallstones. By contrast, 
low levels of cholesterol were observed in the combination group, suggesting rapid dissolution of gallstones and 
recycling of cholesterol to the liver. Furthermore, levels of most bile acid subclasses were increased in the PUFA, 
UDCA, and combination groups. As few studies to date have analysed bile acid subclasses, our findings provide a 
basis for further detailed analyses of bile acids.
Although gallstone formation is associated with metabolic syndrome, the mechanisms of this association are 
unclear. Here, we show that combination UDCA/PUFA treatment suppressed hepatic lipogenesis and modulated 
hepatic lipid metabolism, thereby alleviating hepatic steatosis and reducing gallstone formation. A previous study 
reports that hepatic insulin resistance is sufficient to increase biliary cholesterol secretion and promote gallstone forma-
tion31. Given that hepatic insulin resistance links dyslipidemia and hepatic steatosis, suppression of hepatic lipogenesis 
by combination treatment may prevent gallstone formation in addition to its beneficial effect on hepatic steatosis.
One limitation of this study is that we did not measure levels of biliary proteins (e.g., mucin), nucleation time, 
and the level of cholesterol monohydrate crystals, which means that we did not analyse the overall gallstone 
formation process. In addition, we did not differentiate between endogenic and exogenic bile acids in the anal-
yses, and we collected and analysed bile from the gallbladder instead of the intrahepatic bile duct. Bile is more 
concentrated in the former than in the latter. In addition, we measured the total phospholipid level but could not 
measure that of lecithin due to the small quantity of bile collected.
In conclusion, treatment with combination of PUFA and UDCA dissolved cholesterol gallstones in mice by 
increasing levels of bile phospholipids and bile acids, decreasing cholesterol saturation, and suppressing mucin 
production without inducing systemic side effects. Our results suggest mechanisms for the therapeutic effects of 
PUFA on gallstones and establish a basis for future clinical trials of the therapeutic effects of the combination of 
PUFA and UDCA in patients with cholesterol gallstones.
Materials and Methods
Animals and diets. C57BL/6J (male, 8-week-old) mice were purchased from Central Laboratory Animal 
Inc. (Seoul, Republic of Korea). Mice (n = 160) were divided into four groups (control, UDCA, PUFA, and UDCA 
and PUFA combined), and 40 mice were assigned to each group. The experiment was conducted for a total of 
20 weeks. A lithogenic diet (LD) was administered to all mice to induce gallstones during the pre-treatment 
stage for 8 weeks before the therapeutic agent was introduced. After 8 weeks, 15 mice in each group were ran-
domly selected and sacrificed to confirm formation of gallstones and evaluate baseline characteristics during 
the pre-treatment stage before administration of the therapeutic agents. The mice were fasted for 12 h and anes-
thetized with ether using a desktop rodent anesthesia ventilator (RWD Life Science Co. Ltd., Shenzhen, China). 
Blood was collected from the vena cava, and bile was collected from the gallbladder. The bile collected from five 
mice was combined and analyzed as a single sample. Separated serum and bile samples were stored at −80 °C. 
The liver and gallbladder were separated and divided into two samples; one was frozen in liquid nitrogen, and the 
other was fixed in 10% formalin. A regular diet (RD) was administered to all remaining mice (n = 100) during the 
12-week treatment stage while the therapeutic agent was administered. After the 12 weeks of treatment, the mice 
were sacrificed as described above.
The LD consisted of 15% anhydrous milkfat, 2.0% corn oil, 1.0% cholesterol, and 0.5% cholic acid, and con-
tained 4,380 kcal/kg (#102136; Dyets, Inc., Bethlehem, PA, USA). The RD consisted of 6.4% crude fat (Laboratory 
Rodent Diets; Woojung Co., Seoul, Korea). The diets were diluted in 0.75% Tween-80 and administered daily by 
oral gavage. Mice in the control group were fed the RD during the treatment stage without the therapeutic agents. 
UDCA (12.5 mg/kg/day; Ursa®, Daewoong Pharm., Seoul, Korea), which contained 2,793 kcal/kg, was admin-
istered to mice in the UDCA group, and 51 mg/kg/day PUFA (Omacor®, Pronova Biocare, Sandefjord, Norway) 
was administered to mice in the PUFA group. The combined treatment group was administered a mixture of 
PUFA (51 mg/kg/day) and UDCA (12.5 mg/kg/day) at a 1:1 ratio.The experimental protocol and study design 
were approved by the Institutional Animal Care and Use Committee of Yonsei University (No. 2015-0238). All 
protocols were carried out in accordance with the relevant guidelines and regulations.
Measurement of body, liver, and gallstone weight. Mouse body weight was measured weekly. After 
8 weeks of consuming a LD, baseline body, liver, and gallstone weights were measured. After treatment for 12 
weeks, final body, liver, and gallstone weights were measured. Gallstone size was assessed using a 6-point scoring 
system: 0 = clear bile; 1 = little sludge; 2 = widespread sludge; 3 = large quantity of sludge; 4 = a few small stones; 
5 = several stones; and 6 = full of stones32.
Hematoxylin and eosin staining of gallbladder tissue. Gallbladder tissue was fixed in 10% formalin 
for 2 days and sliced into six strips, which were embedded in paraffin and cut into 4-mm-thick sections. Sections 
were deparaffinized, rehydrated, and stained with hematoxylin and eosin. Stained sections were dehydrated, 
cleaned, mounted, and examined by light microscopy.
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Measurement of mucin gene expression. Total RNA was extracted from gallbladder tissue using TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA) and treated with RNase-free DNase (Promega, Madison, WI, USA) for 
30 min at 37 °C. Next, RNA was cleaned using an RNeasy Kit (Qiagen, Germantown, MD, USA). Reverse tran-
scription reaction was performed using a commercially available high-capacity cDNA Synthesis Kit (Thermo 
Fisher Scientific, Rockford, IL, USA). Levels of Muc2, Muc5ac, Muc5b, and Muc6 mRNA were quantified by 
TaqMan polymerase chain reaction (PCR) using the 18S ribosomal RNA gene (Rn18s) as an internal control. Data 
generated were analysed using Applied Biosystems 7300 software (Applied Biosystems, Foster City, CA, USA). 
The relative expression levels of target genes were determined using the comparative threshold cycle method. 
PCR primers and fluorogenic probes specific for the following genes were purchased from Applied Biosystems: 
Muc2 (Mm00458299_m1), Muc5ac (Mm01276725_g1), Muc5b (Mm00466391_m1), Muc6 (Mm00725165_m1), 
and Rn18s (Mm03928990_g1).
Quantification of total phospholipids, cholesterol, and bile acid in bile and serum. Total phos-
pholipid, cholesterol, and bile acid levels in bile and serum were determined using a colorimetric assay (BioAssay 
Systems, Hayward, CA, USA). Briefly, bile samples were diluted 10-fold and treated with working reagent. The 
absorbance of the samples was measured using a microplate spectrometer (Epoch, BioTek, Winooski, VT, USA) 
at 570 nm and 340 nm for quantification of phospholipids and cholesterol, respectively.
phospholipid analyses. The Folch lipid extraction method for obtaining phospholipid classes (e.g., 
phosphatidylcholine, lysophosphatidylcholine, ceramide 1-phosphate, cholesterol) and the bile acid extrac-
tion method were performed (Supplementary Fig. 1). All lipids were extracted with organic solvents and used 
a Hypersil GOLD column for liquid chromatography triple quadrupole mass spectrometry (LC/QqQ-MS/MS; 
Supplementary Data). All phospholipids, cholesteryl ester, and cholesterol were analyzed in positive ion mode, 
and bile acid was analyzed in negative ion mode.
Data analysis and statistical modeling. Primary analysis of high-throughput sequencing data was per-
formed with Bowtie233, samtools34 and DESeq35 packages. Bowtie2 is an ultrafast and memory-efficient tool for 
aligning sequencing reads to long reference sequences, and samtools provides various utilities for manipulat-
ing alignments in the mapping file, including sorting, merging, and indexing. DESeq applies a statistical model 
to identify differential signals in RNA-seq data using a negative binomial distribution with variance and mean 
linked by local regression. Raw FASTQ files were generated using an Illumina NextSeq instrument (San Diego, 
CA, USA), and sequence reads were mapped to the UCSC mm10 reference genome and sorted using Bowtie2 
and samtools. After sequence reads were mapped to the reference genome, HtSeq was used to count the reads 
mapped to each gene, and DESeq was used for analyses of differentially expressed genes (DEGs). Pairwise com-
parisons were performed between the control group and the three treatment groups to identify significant DEGs 
(P < 0.05).
Gene ontology enrichment analyses of DeGs. Gene ontology (GO) enrichment analysis of DEGs was 
performed. Enriched GO terms for common DEGs in all treatment groups were identified using hypergeometric 
tests between DEGs and GO-annotated gene sets with a cut-off P = 0.05.
construction of protein-protein interaction networks. The STRING 9.1 network database36 is the 
one of the largest databases of direct (i.e., physical) and indirect (i.e., functional) protein-protein interactions 
and contains data from various sources including genomic context predictions, high-throughput experiments, 
co-expression analyses, and known databases. The database covers 9.6 million proteins from more than 2,031 
organisms. We used this database to identify protein-protein interaction networks of the identified DEGs. As 
our gene sets were represented by gene symbols, the Ensembl protein identifiers in the original STRING data-
base were converted into gene symbols using mapping information in Mouse Genome Informatics (http://www.
informatics.jax.org).
Statistical analyses. Data are expressed as mean ± standard deviation. Differences between groups were 
analyzed using one-way ANOVA with a post-hoc test or Mann-Whitney U-tests, as appropriate. Statistical signif-
icance was defined as P ≤ 0.05. Analyses were performed using SPSS (v. 18.0) software.
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